Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Irene Lara-Sáez *Charles Institute of Dermatology, School of Medicine, University College Dublin, Belfield, Dublin D04 V1W8, Ireland.ORCID 0000-0002-9557-1388
Ángeles Mencía *Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.ORCID 0000-0002-9977-9514
Enrique RecueroBiomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.ORCID 0009-0001-3663-4713
Yinghao LiCharles Institute of Dermatology, School of Medicine, University College Dublin, Belfield, Dublin D04 V1W8, Ireland.ORCID 0000-0001-9584-8159
Marta GarcíaCB06/07/0019 Unit, Centro de Investigación Biomédica en Red en Enfermedades Raras, Madrid 28029, Spain.
Marta OteoBiomedical Applications and Pharmacokinetics Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.
Marta I GallegoUnidad de Histología, Unidades Centrales Científico Tecnológicas, Instituto de Salud Carlos III, Madrid 28220, Spain.ORCID 0000-0003-0143-2553
Ana Belén EnguitaPathology Department, University Hospital "12 de Octubre", Madrid 28041, Spain.
Diana de Prado-VerdúnBiomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.ORCID 0009-0005-1848-1732
Sigen AResearch and Clinical Translation Center of Gene Medicine and Tissue Engineering, School of Public Health, Anhui University of Science and Technology, Huainan 232001, China.
Wenxin WangCharles Institute of Dermatology, School of Medicine, University College Dublin, Belfield, Dublin D04 V1W8, Ireland.ORCID 0000-0002-5053-0611
Ramón García-EscuderoBiomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.ORCID 0000-0001-5640-6542
Rodolfo MurillasBiomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.ORCID 0000-0001-9813-1006
Mirentxu SantosBiomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain.
Funding
China Scholarship Council (CSC) CSC202008300033)Debra International (DEBRA) Garcia-Diez 1Fundación Científica Asociación Española Contra el Cáncer (AECC) IDEAS211079SANTMEC | Instituto de Salud Carlos III (ISCIII) CB16/12/00228/CIBERONCMEC | Instituto de Salud Carlos III (ISCIII) PI15/00993MEC | Instituto de Salud Carlos III (ISCIII) PI21/00171MEC | Instituto de Salud Carlos III (ISCIII) PI21/00764Science Foundation Ireland (SFI) 18/FIP/3576Science Foundation Ireland (SFI) 19/FFP/6522
6 · The paper itself
Abstract
Functional analysis in mouse models is necessary to establish the involvement of a set of genetic variations in tumor development. A modeling platform to facilitate and cost-effectively analyze the role of multiple genes in carcinogenesis would be valuable. Here, we present an innovative strategy for lung mutagenesis using CRISPR/Cas9 ribonucleoproteins delivered via cationic polymers. This approach allows the simultaneous inactivation of multiple genes. We validate the effectiveness of this system by targeting a group of tumor suppressor genes, specifically
Indexed as
CRISPR-Cas SystemsLung NeoplasmsMutagenesisPTEN PhosphohydrolaseSmall Cell Lung CarcinomaTumor Suppressor Protein p53AnimalsDisease Models, AnimalGene EditingHumansMiceRetinoblastoma-Like Protein p107Retinoblastoma ProteinPTEN PhosphohydrolasePten protein, mouseRbl1 protein, mouseRetinoblastoma-Like Protein p107Retinoblastoma ProteinTrp53 protein, mouseTumor Suppressor Protein p53CRISPR/Cas9 ribonucleoproteinin vivo gene editinglung cancer modelsSCLC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models. · full record | OpenQuestion